Predictive Value of Preoperative Volume-Based 18F-2-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography Parameters in Patients with Resectable Lung Adenocarcinoma

다국어 초록 (Multilingual Abstract)

Purpose This study aimed to investigate the prognostic value of metabolic tumor volume (MTV) and total lesion glycolysis(TLG), which are volume-based PET parameters, using 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) in patients with surgically resectable lung adenocarcinoma.
Methods We retrospectively evaluated 149 patients with lung adenocarcinoma who underwent 18F-FDG PET/CT beforesurgical resection. Maximum standardized uptake value (SUVmax), MTV, and TLG of the primary tumor with thresholdvalue of SUVmax 30, 40, and 50% were calculated, respectively. To compare the predictive performance of volumebasedPET parameters, recurrence-free survival was assessed using the Kaplan-Meier method.
Results The study included 70 males and 79 females with an average age of 65.8 years. The median follow-up time was45.4 months. Recurrence was observed in 53 patients (35.6%). The mean ± SD SUVmax, MTV30%, and TLG30% of theentire cohort were 4.79 ± 2.94, 19.45 ± 24.85, and 56.43 ± 101.88, respectively. The cut-off values of MTV30% andTLG30% for recurrence were 11.07 ad 30.56, respectively. The 1-year recurrence-free survival (RFS) rate was 96.5%in low-MTV30% patients compared with 86.2% in high-MTV30% patients (p = 0.018) and 96.0% in low-TLG30% patientscompared with 88.5% in high-TLG30% patients (p < 0.001). On univariate and multivariate analysis, TLG30% (HR, 2.828,p < 0.001; HR, 2.738, p < 0.001, respectively) was an independent prognostic factor for predicting recurrence-freesurvival (RFS).
Conclusion TLG30% value was observed to be a significant prognostic factor for RFS in patients with lung adenocarcinomatreated by surgical resection.

참고문헌 (Reference)

1 Hyun SH, "Volume-based assessment by 18F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer" 41 : 50-58, 2014

2 Jonnalagadda S, "Validation of the lymph node ratio as a prognostic factor in patients with N1nonsmall cell lung cancer" 117 : 4724-4731, 2011

3 Taylor MD, "Tumor recurrence after complete resection for non-small cell lung cancer" 93 : 1813-1820, 2012

4 Asamura H, "The International Association for the Study of Lung Cancer lung cancer staging project: proposals for the revision of the N descriptors in the forthcoming 8th edition of the TNM classification for lung cancer" 10 : 1675-1684, 2015

5 Huang W, "Standard uptake value and metabolic tumor volume of 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer" 38 : 1628-1635, 2011

6 Isaka M, "Risk factors for local recurrence after lobectomy and lymph node dissection in patients with non-small cell lung cancer: implications for adjuvant therapy" 115 : 28-33, 2018

7 Dziedzic DA, "Risk factors for local and distant recurrence after surgical treatment in patients with non-small-cell lung cancer" 17 : e157-e167, 2016

8 Endo C, "Results of long-term follow-up of patients with completely resected non-small cell lung cancer" 93 : 1061-1068, 2012

9 Vesselle H, "Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index" 3 : 971-978, 2008

10 Im HJ, "Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer: a meta-analysis" 42 : 241-251, 2015

11 Kim K, "Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer" 33 : 613-620, 2012

12 Park SY, "Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer" 56 : 45-49, 2015

13 Lin Y, "Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer" 32 : 5087-5091, 2012

14 Wang XY, "Prognostic value of metabolic variables of 18F-FDG PET/CT in surgically resected stage I lung adenocarcinoma" 96 : e7941-, 2017

15 Zhang H, "Prognostic value of metabolic tumor burden from 18F-FDG PET in surgical patients with non-small-cell lung cancer" 20 : 32-40, 2013

16 Mordant P, "Prognostic factors after surgical resection of N1 non-small cell lung cancer" 41 : 696-701, 2015

17 Su S, "Patterns of survival and recurrence after surgical treatment of early stage non-small cell lung carcinoma in the ACOSOG Z0030(ALLIANCE) trial" 147 : 747-752, 2014

18 Ettinger DS, "Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology" 15 : 504-535, 2017

19 Lee P, "Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer" 13 : 52-58, 2012

20 Lee P, "Metabolic tumor burden predicts for disease progression and death in lung cancer" 69 : 328-333, 2007

21 Wisnivesky JP, "Lymph node ratio as a prognostic factor in elderly patients with pathological N1 non-small cell lung cancer" 66 : 287-293, 2011

22 UyBico SJ, "Lung cancer staging essentials: the new TNM staging system and potential imaging pitfalls" 30 : 1163-1181, 2010

23 Firouzian A, "Insight on automated lesion delineation methods for PET data" 4 : 69-, 2014

24 Adebonojo SA, "Impact of revised stage classification of lung cancer on survival: a military experience" 115 : 1507-1513, 1999

25 Schuurbiers OC, "Glucose metabolism in NSCLC is histology-specific and diverges the prognostic potential of 18FDG-PET for adenocarcinoma and squamous cell carcinoma" 9 : 1485-1493, 2014

26 Fitzmaurice C, "Global, Regional, and National Cancer Incidence, Mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A systematic analysis for the global burden of disease study" 2018

27 Chung HW, "FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma" 140 : 89-98, 2014

28 Koh YW, "Differential expression and prognostic significance of GLUT1 according to histologic type of non-smallcell lung cancer and its association with volume-dependent parameters" 104 : 31-37, 2017

29 Han B, "Correlation of 18F-FDG PET activity with expressions of survivin, Ki67, and CD34 in nonsmall-cell lung cancer" 30 : 831-837, 2009

30 Siegel RL, "Cancer statistics, 2017" 67 : 7-30, 2017